Quantitative real‐time reverse‐transcription polymerase chain reaction for diagnosis of BCR‐ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation
- 14 January 2003
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 70 (1) , 1-10
- https://doi.org/10.1034/j.1600-0609.2003.02811.x
Abstract
Real‐time reverse‐transcription polymerase chain reaction (RT‐PCR) (qPCR) of the BCR‐ABL mRNA is a suitable technique to measure the amount of circulating leukemic cells in chronic myelogenous leukemia (CML). In this study, we evaluated a BCR‐ABL‐specific qPCR method using the LightCycler technology in 95 patients with Philadelphia chromosome positive acute leukemia (n = 7) or CML in different stages (n = 88). Primers and hybridization probes were chosen to detect the most prevalent variants of BCR‐ABL (b2a2, b3a2, b2a3, b3a3, e19a2, e1a2) with a sensitivity of 10−5 for b2a2 and b3a2. With median BCR‐ABL/G6PDH ratios of 10.7% in the untreated chronic phase, 43.2% in the newly diagnosed accelerated phase, and 131.4% in newly diagnosed blast crisis the BCR‐ABL mRNA levels varied significantly between different stages of CML whereas no difference was found between blast crisis and untreated acute leukemias (136.9%). There was a strong relationship between qPCR results and cytogenetics in patients treated with imatinib, interferon‐α, or following allografting. Thirteen patients with CML were sequentially examined by qPCR following myeloablative or non‐myeloablative allogeneic peripheral blood stem cell transplantation. Five patients received donor lymphocytes and became BCR‐ABL negative as confirmed by nested RT‐PCR. The gradual disappearance of BCR‐ABL positive cells could be monitored by qPCR following non‐myeloablative transplantation. Comparison of BCR‐ABL levels with the degree of donor chimerism showed that 91% of samples with complete donor chimerism were BCR‐ABL negative. In 22% of BCR‐ABL negative samples chimerism between 71% and 98% was observed, indicating the persistence of normal recipient's hematopoietic cells. In conclusion, the qPCR protocol used in this study is a reliable and fast method for monitoring molecular response in CML.Keywords
This publication has 41 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibodyBone Marrow Transplantation, 2001
- Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBritish Journal of Haematology, 1999
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999
- Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assayLeukemia, 1999
- Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCRBritish Journal of Haematology, 1998
- A Chance of Cure for Every Patient with Chronic Myeloid Leukemia?New England Journal of Medicine, 1998
- Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 1997
- An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemiaEuropean Journal of Haematology, 1996
- Characteristics of accelerated disease in chronic myelogenous leukemiaCancer, 1988